Low-dose add-back therapy during postoperative GnRH agonist treatment
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Low-dose add-back therapy during postoperative GnRH agonist treatment could lower the risk of add-back-induced endometriosis recurrence and reduce treatment dropout compared with a regular dose. However, the effect of low-dose add-back therapy is still unknown. The aim of this study was to determine whether low-dose add-back therapy can also effectively relieve the hypoestrogenic side effects and simultaneously maintain a therapeutic response of GnRH agonist treatment. MATERIALS AND METHODS: This analysis was a prospective cohort study. During postoperative GnRH agonist treatment, a total of 107 women were prescribed add-back therapy [oral combination tablet; estradiol valerate (1 mg) and medroxyprogesterone acetate (2.5 mg)] (Indivina; Orion, Espoo, Finland) for 20 weeks. Patients in the low dose add-back therapy group were prescribed the tablet once a day, and patients in the regular dose group were given the tablet twice a day. Hypoestrogenic side effects, such as hot flashes and insomnia, were recorded. Patients were also questioned regarding their pelvic symptoms and pain to evaluate the possibility of endometriosis recurrence. Lumbar spine (L2-L4) bone mineral density was measured using dual X-ray absorptiometry. The dropout rates in both groups were also evaluated. RESULTS: The incidence of hypoestrogenic side effects was lower in the low dose group compared with the regular dose group, including hot flashes (19.2% vs. 21.8%, p = 0.741) and insomnia (15.4% vs. 18.2%, p = 0.699), although there were no significant difference between the groups. In addition, a higher number of patients in the regular dose group dropped out of treatment compared to the low dose group (14.5% and 9.6%, respectively, p = 0.435). The patients in both groups had a significant loss of mean bone mineral density during therapy (p < 0.001 and p = 0.018 for the low dose and regular dose groups, respectively). CONCLUSION: Low dose add-back therapy could effectively ameliorate hypoestrogenic side effects and simultaneously maintain the therapeutic response of GnRH agonist treatment. The treatment dropout was lower compared with a regular dose. Therefore, low dose add-back therapy can be considered a treatment choice during postoperative GnRH agonist treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hormone treatment of endometriosis: The estrogenthreshold hypothesis
Barbieri, R. L. (1992) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(92)91706-g · Cited by 335
Commonly Used Types of Postmenopausal Estrogen for Treatment of Hot Flashes: Scientific Review
Nelson, H. D. (2004) · JAMA · doi:10.1001/jama.291.13.1610 · Cited by 296 · cited 1×
“Vasomotor symptoms, hot flashes, and vaginal dryness are all bothersome side effects and are directly related to the rapid drop in estrogen levels [23,24].”
BackgroundDosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness
Biberoglu, K. O., & Behrman, S. J. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90478-6 · Cited by 267
Gonadotrophin-releasing hormone analogues for pain associated with endometriosis
Veth, V. B., van de Kar, M. M., McDonnell, R., Julania, S., & Hart, R. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008475.pub2 · Cited by 182 · cited 1×
“However, the continuous administration of medroxyprogesterone acetate appears to reverse the beneficial effects of GnRH agonist; moreover, norethindrone has adverse effects on lipid profiles [22].”
BackgroundAdd-back therapy in the treatment of endometriosis-associated pain
Zupi, E., Marconi, D., Sbracia, M., Zullo, F., De Vivo, B., Exacustos, C., & Sorrenti, G. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.03.062 · Cited by 103
Bedaiwy, M. A., & Casper, R. F. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.12.030 · Cited by 76 · cited 2×
“Regarding the bothersome vasomotor symptoms that are associated with GnRH agonist treatment, estrogen-containing add-back therapy might be a better option than progestin-alone add-back therapy [2,10,18,19].”
BackgroundGonadotropin-releasing hormone agonist and add-back therapy: what do the data show?
Surrey, E. S. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32833b35a7 · Cited by 64
GnRH analogs: Options for endometriosis-associated pain treatment
Batzer, F. R. (2006) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2006.07.007 · Cited by 42
Cited by
Reevaluating response and failure of medical treatment of endometriosis: a systematic review
Becker, C. M., Gattrell, W. T., Gude, K., & Singh, S. S. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.05.004 · Cited by 302
Estrogen Effects on Wound Healing
Horng, H.-C., Chang, W.-H., Yeh, C.-C., Huang, B.-S., Chang, C.-P., Chen, Y.-J., Tsui, K.-H., & Wang, P.-H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112325 · Cited by 208
Self-citationBedaiwy, M. A., Allaire, C., & Alfaraj, S. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.12.024 · Cited by 126
Burghaus, S., Schäfer, S. D., Beckmann, M. W., Brandes, I., Brünahl, C., Chvatal, R., Drahoňovský, J., Dudek, W., Ebert, A. D., Fahlbusch, C., et al. (2021) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1380-3693 · Cited by 69
Metadata
- Authors
- Tsai, H.-W., Wang, P.-H., Huang, B.-S., Twu, N.-F., Yen, M.-S., & Chen, Y.-J.
- Venue
- Taiwanese Journal of Obstetrics and Gynecology
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 55
- Issue
- 1
- Pages
- 55-59
- ISSN
- 1028-4559 (ISSN-L)
- OpenAlex
- W2277199366
- Cited by
- 21
- References
- 8
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.